Scilight Press

Author Information

Received: 17 Oct 2022 | Accepted: 15 Nov 2022 | Published: 21 Dec 2022

Abstract

Graphical Abstract

Image Viewer

Open in new tab

Download Image

Keywords

hypertension | Sodium glucose cotransporter 2 inhibitor

References 

• 1.
  Vallon V.; Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu. Rev. Physiol., 2021, 83: 503-528.
• 2.
  Neal B.; Perkovic V.; Mahaffey K.W.; et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med., 2017, 377(7): 644-657.
• 3.
  Wanner C.; Inzucchi S.E.; Lachin J.M.; et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med., 2016, 375(4): 323-334.
• 4.
  Wiviott S.D.; Raz I.; Bonaca M.P.; et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med., 2019, 380(4): 347-357.
• 5.
  McMurray J.J.V.; Solomon S.D.; Inzucchi S.E.; et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 2019, 381(21): 1995-2008.
• 6.
  Anker S.D.; Butler J.; Filippatos G.; et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med., 2021, 385(16): 1451-1461.
• 7.
  Solomon S.D.; Vaduganathan M.; Claggett B.L.; et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC: Heart Failure, 2022, 10(3): 184-197.
• 8.
  Kario K.; Okada K.; Kato M.; et al. 24-Hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation, 2018, 139(18): 2089-2097.
• 9.
  Sternlicht H.; Bakris G.L. Blood pressure lowering and sodium-glucose co-transporter 2 (SGLT2is)inhibitors: more than osmotic diuresis. Curr. Hypertens. Rep., 2019, 21(2): 12.
• 10.
  Akbari A.; Rafiee M.; Sathyapalan T.; et al. Impacts of sodium/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: a systematic review and meta-analysis. J. Diabetes Res., 2022, 2022: 7520632.
• 11.
  Bailey C.J. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes, Obes. Metab., 2019, 21(6): 1291-1298.
• 12.
  Corry D.B.; Eslami P.; Yamamoto K.; et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J. Hypertens., 2008, 26(2): 269-275.
• 13.
  Kang D.H.; Park S.K.; Lee I.K.; et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J. Am. Soc. Nephrol., 2005, 16(12): 3553-3562.
• 14.
  Herrington W.G.; Savarese G.; Haynes R.; et al. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. Eur. J. Heart Failure, 2021, 23(8): 1260-1275.
• 15.
  Chakraborty S.; Galla S.; Cheng X.; et al. Salt-responsive metabolite, β-hydroxybutyrate, attenuates hypertension. Cell Rep., 2018, 25(3):677-689.e4.
• 16.
  McCarthy C.G.; Chakraborty S.; Singh G.; et al. Ketone body β-hydroxybutyrate is an autophagy-dependent vasodilator. JCI insight, 2021, 6(20): e149037.
• 17.
  Grassi G. The sympathetic nervous system in hypertension: roadmap update of a long journey. Am. J. Hypertens., 2021, 34(12): 1247-1254.
• 18.
  Chilton R.; Tikkanen I.; Cannon C.P.; et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes, Obes. Metab., 2015, 17(12): 1180-1193.
• 19.
  Herat L.Y.; Magno A.L.; Rudnicka C.; et al. SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC: Basic to Translational Science, 2019, 5(2): 169-179.
• 20.
  Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J. Cardiol., 2017, 71(5): 471-476.
• 21.
  Nguyen T.; Wen S.; Gong M.; et al. Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice. Diabetes, Metab. Syndr. Obes.: Targets Ther., 2020, 13: 2781-2799.
• 22.
  Yaribeygi H.; Atkin S.L.; Butler A.E.; et al. Sodium-glucose cotransporter inhibitors and oxidative stress: an update. J. Cell. Physiol., 2019, 234(4): 3231-3237.
• 23.
  Griendling K.K.; Camargo L.L.; Rios F.J.; et al. Oxidative stress and hypertension. Circ. Res., 2021, 128(7): 993-1020.
• 24.
  Viola A.; Monticone S.; Burrello J.; et al. Renin and aldosterone measurements in the management of arterial hypertension. Horm. Metab. Res., 2015, 47(6): 418-426.
• 25.
  Patel S.; Rauf A.; Khan H.; et al. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomed. Pharmacother., 2017, 94: 317-325.
• 26.
  Puglisi S.; Rossini A.; Poli R.; et al. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front. Endocrinol., 2021, 12: 738848.
• 27.
  Hou Y.C.; Zheng C.M.; Yen T.H.; et al. Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection. Int. J. Mol. Sci., 2020, 21(21): 7833.
• 28.
  Durante W.; Behnammanesh G.; Peyton K.J. Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling. Int. J. Mol. Sci., 2021, 22(16): 8786.
• 29.
  Prado A.F.; Batista R.I.M.; Tanus-Santos J.E.;et al. Matrix metalloproteinases and arterial hypertension: role of oxidative stress and nitric oxide in vascular functional and structural alterations. Biomolecules, 2021, 11(4): 585.
• 30.
  Endemann D.H.; Schiffrin E.L. Endothelial dysfunction. J. Am. Soc. Nephrol., 2004, 15(8): 1983-1992.
• 31.
  Touyz R.M.; Alves-Lopes R.; Rios F.J.; et al. Vascular smooth muscle contraction in hypertension. Cardiovasc. Res., 2018, 114(4): 529-539.
• 32.
  Reina-Couto M.; Afonso J.; Carvalho J.; et al. Interrelationship between renin-angiotensin-aldosterone system and oxidative stress in chronic heart failure patients with or without renal impairment. Biomed. Pharmacother., 2021, 133: 110938.
• 33.
  Zhao Y.; Li L.; Lu Z.S.; et al. Sodium-glucose cotransporter 2 inhibitor canagliflozin antagonizes salt-sensitive hypertension through modifying transient receptor potential channels 3 mediated vascular calcium handling. J. Am. Heart Assoc., 2022, 11(15): e025328.
• 34.
  Alqudsi M.; Velez J.C.Q.; Navarrete J. Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i). Current Opinion in Cardiology, 2021, 36(4): 420-428.